Mark Reed
Podiatrist · Placentia, CANPI 1891771713
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,373 of the $1,903 with a category attached, or 72.1%. 10 manufacturers reported payments, led by Paragon 28, Inc. at 52.5% of the total. Reporting peaked in 2019 at $1,017 and has fallen 86.8% since, to $134 in 2025.
Across 21 payments — averaging $90.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragon 28, Inc.$1K
- Smith+Nephew$280
- Stryker$152
- Organogenesis Inc.$124
- Integra Lifesciences Corporation$119
- UCB, Inc.$101
- plus $127 from 4 others
What the payments were for
- Travel & lodging$53028%
- Food & beverage$1,37372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragon 28, Inc. | 5 | $1,000 |
| Smith+Nephew | 2 | $280 |
| Stryker | 3 | $152 |
| Organogenesis Inc. | 1 | $124 |
| Integra Lifesciences Corporation | 1 | $119 |
| UCB, Inc. | 1 | $101 |
| Misonix Inc | 4 | $58 |
| Medical Device Business Services, Inc. | 2 | $40 |
| Viiv Healthcare Company | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PICO$145
- GRAFIX PL$135
- Oasis$135
- Stravix$135
- Precision MIS Bunion$134
- PuraPly$124
- SALTO TALARIS TOTAL ANKLE PROSTHESIS$119
- CADENCE ANKLE REPLACEMENT SYSTEM$119
- HALLU-LOCK$119
- PANTA NAIL$119
- TOTAL FOOT SYSTEM$119
- Fintepla$101
How this compares
$1,903 in reported general payments places this provider in the 65th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitroglycerin PatchNitroglycerin | 137 | $14,723 |
| Nitro-BidNitroglycerin | 22 | $1,538 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $151 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $146 |
| Ciprofloxacin Hcl | 20 | $100 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Placentia
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.